Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News
July 28th 2025

Survival Gains in Multiple Myeloma Highlight Progress and Persistent Disparities

July 8th 2025

Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD

July 7th 2025

Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD

July 1st 2025

Lower Tregs Linked With Survival in Multiple Myeloma

June 30th 2025

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

AJMC Insights logo displayed on a blue abstract background with light and dark wave patterns.
Video Interviews
View All
July 30th 2025

Linvoseltamab Approval Expands Access, Increases Competition in BCMA Bispecifics Space: Sundar Jagannath, MBBS

July 29th 2025

Linvoseltamab May Bring Multiple Myeloma Care Closer to Home: Sundar Jagannath, MBBS

July 29th 2025

Key Takeaways From CEPHEUS: Subgroup Analysis

July 29th 2025

Expert Perspectives on Balancing QOL, Convenience, and Depth of Treatment Response

July 22nd 2025

Therapy Selection and Management Strategies for Transplant-Ineligible Older Patients

July 22nd 2025

Balancing Deeper Response and MRD Negativity With Toxicity Risks in Clinical Decision-Making

July 18th 2025

Practical Considerations, Future Outlook for Linvoseltamab in Multiple Myeloma Care: Hans Lee, MD

July 15th 2025

Navigating First-Line Therapy Guidelines and Treatment Considerations in High-Risk Cytogenetics

July 15th 2025

Evolving Treatment Strategies in Transplant-Ineligible NDMM: Expert Insights From CEPHEUS, IMROZ and BENEFIT

July 8th 2025

Advancing Frontline Therapy in Transplant-Eligible Myeloma and Emerging Trends in Smoldering Myeloma Management

Continuing Medical Education
View All
August 3rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 3rd 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
August 3rd 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer
August 3rd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
August 3rd 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

4 experts in this video
July 8th 2025

Managing Early Relapse in Transplant-Eligible MM and the Influence of Clonal Evolution

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how early relapse in standard-risk patients represents a failure of current risk assessment methods and may require advanced sequencing technologies to identify hidden high-risk features that traditional fluorescence in situ hybridization testing misses.
Mansi Shah, MD
June 30th 2025

Why a Patient With Multiple Myeloma Might Decline Stem Cell Transplant: Mansi Shah, MD

Hayden E. Klein Laura Joszt, MA Mansi Shah, MD
Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, says Mansi Shah, MD.
These studies highlight that multiple myeloma outcomes are not solely determined by disease biology or available therapies. | Image Credit: wladimir1804 - stock.adobe.com
June 28th 2025

Highlighting Disparities in Myeloma Outcomes, the Impacts of Comorbidities

Kimberly Rath, PharmD
Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 American Society of Clinical Oncology annual meeting.
Mansi Shah, MD
June 27th 2025

How Transplant, CAR T, and Bispecifics Fit Into Myeloma Care: Mansi Shah, MD

Hayden E. Klein Laura Joszt, MA Mansi Shah, MD
Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple myeloma.
4 experts in this video
June 27th 2025

Balancing Timing of ASCT: Insights on Delayed Transplantation and Long-Term Treatment Outcomes

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how autologous stem cell transplant (ASCT) deferral should be approached cautiously with concrete medical reasons, as transplant continues to provide superior progression-free survival and potentially curative outcomes for a subset of patients.
4 experts in this video
June 27th 2025

Tailoring Maintenance Therapy by Patient Risk: Lenalidomide Alone vs Combination Approaches

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how maintenance therapy should be tailored based on risk profiles, with standard-risk patients receiving single-agent lenalidomide while high-risk patients may benefit from combination maintenance strategies to achieve more durable responses.
Dr Xavier Leleu
June 25th 2025

Self-Administered Subcutaneous Isatuximab May Ease Multiple Myeloma Treatment Burden: Xavier Leleu, MD, PhD

Brooke McCormick Xavier Leleu, MD, PhD
On-body delivery systems for subcutaneous isatuximab could enable patient self-administration, according to Xavier Leleu, MD, PhD, improving convenience and transforming treatment for relapsed/refractory multiple myeloma.
Dr Xavier Leleu
June 25th 2025

Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD

Brooke McCormick Xavier Leleu, MD, PhD
The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, according to Xavier Leleu, MD, PhD.
Francesco Sparano, MSc
June 25th 2025

Quality of Life Disparities Persist in R/R Multiple Myeloma Despite Universal Health Care: Francesco Sparano, MSc

Brooke McCormick Francesco Sparano, MSc
Patients with relapsed/refractory myeloma from lower socioeconomic groups face worse quality of life, even in countries with universal health care, according to Francesco Sparano, MSc, of the Italian-based GIMEMA Foundation.
Dr Sundar Jagannath
June 25th 2025

Long-Term Data Support Cilta-Cel Use in R/R Multiple Myeloma: Sundar Jagannath, MBBS

Brooke McCormick Sundar Jagannath, MBBS
Long-term CARTITUDE-1 data show ciltacabtagene autoleucel (cilta-cel) may offer lasting remission and survival in relapsed/refractory multiple myeloma, according to Sundar Jagannath, MBBS, of the Icahn School of Medicine at Mount Sinai.
4 experts in this video
June 20th 2025

The Role of MRD Status in Post-ASCT Treatment Decisions and Clinical Integration

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how minimal residual disease (MRD) status can guide post-transplant treatment decisions, particularly for high-risk patients who don’t achieve MRD negativity and patients considering discontinuation of long-term maintenance therapy.
4 experts in this video
June 20th 2025

Evaluating First-Line Treatment Options: Quadruplet vs Triplet Regimens and NCCN Guidelines

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how quadruplet regimens show improved efficacy over triplet regimens without significantly increased safety concerns, with anti-CD38 antibodies being well tolerated and NCCN guidelines now recommending 4-drug regimens for transplant-eligible patients.
Westin Forrestal Princeton | Image: Westin
June 19th 2025

Value-Based Care Calls for Putting Novel Therapies Closer to Patients

Mary Caffrey
Coverage from IVBM Princeton, held May 8, 2025.
Surbhi Sidana, MD, MBBS, Stanford University
June 19th 2025

CARTITUDE-4 Data Solidify Cilta-cel’s Role in RRMM: Surbhi Sidana, MD, MBBS

Maggie L. Shaw Surbhi Sidana, MD, MBBS
Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to CARTITUDE-4 and insight on how this phase 3 investigation builds on previous findings of CAR T vs standard-of-care findings in relapsed/refractory multiple myeloma (RRMM)
Saad Z. Usmani, MD, MBA, FACP, FASCO, Memorial Sloan Kettering Cancer Center
June 18th 2025

DVRd vs VRd in Transplant-Ineligible Myeloma: Insights From Saad Z. Usmani, MD, MBA

Maggie L. Shaw Saad Z. Usmani, MD, MBA, FACP, FASCO
CEPHEUS trial lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, explains how the trial both builds on current knowledge of newly diagnosed multiple myeloma and how transplant-ineligible status may affect therapeutic decision-making.
4 experts in this video
June 13th 2025

Treatment Approaches and Goals: Transplant-Eligible vs. Transplant-Ineligible Patients

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how treatment strategies differ between transplant-eligible and transplant-ineligible multiple myeloma patients, with transplant eligibility determined by functional status rather than age alone, and how quadruple therapy regimens are increasingly used for transplant-eligible patients to achieve deep, durable responses.
4 experts in this video
June 13th 2025

The Role of ASCT in Frontline Myeloma: Comparative Risks and Benefits with Other Standard Treatment Approaches

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP
Panelists discuss how autologous stem cell transplant remains essential in frontline multiple myeloma management despite improved quadruple therapy outcomes, emphasizing that current evidence still supports transplantation for eligible patients rather than deferring it.
Mansi Shah, MD
June 11th 2025

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

Laura Joszt, MA Hayden E. Klein Mansi Shah, MD
Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.
The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com
June 7th 2025

Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

Jared Kaltwasser
A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line autologous stem cell transplant (auto-SCT).
IVBM Phoenix logo | Image: AJMC
May 19th 2025

Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape Evolves

Laura Joszt, MA
AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com
May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD
Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Pieter Sonneveld, MD, PhD
May 15th 2025

Benefits of Continuing Subcutaneous Daratumumab After Initial Quad Therapy: Pieter Sonneveld, MD, PhD

Pieter Sonneveld, MD, PhD Rose McNulty Mary Caffrey
Pieter Sonneveld, MD, PhD, professor of hematology and chair of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, discussed the continued use of subcutaneous daratumumab following initial treatment, as well as the changing landscape of multiple myeloma treatment.
Pieter Sonneveld, MD, PhD
May 5th 2025

"Exceptionally Long" PFS Projected With Daratumumab Quadruplet for Multiple Myeloma: Pieter Sonneveld, MD, PhD

Pieter Sonneveld, MD, PhD Mary Caffrey Rose McNulty
Pieter Sonneveld, MD, PhD, chair of the Erasmus MC Cancer Institute, discussed the findings of a study modeling long-term progression-free survival (PFS) in patients with multiple myeloma (MM) treated with a daratumumab quadruplet regimen.
Ajai Chari, MD
May 1st 2025

Considerations for Real-World MM Treatment: Ajai Chari, MD

Kyle Munz Ajai Chari, MD
Because clinical trials do not mimic the real-world application of multiple myeloma treatments, Ajai Chari, MD, discussed the variety of patient factors clinicians should consider in their practice.
Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com
April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD
When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Health equity concept | image credit: VectorMine - stock.adobe.com
April 7th 2025

Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

Kyle Munz Ajai Chari, MD
Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial for maximizing their impact in multiple myeloma (MM).
Targeting GPRC5D Holds Promise in Multiple Myeloma
April 3rd 2025

Targeting GPRC5D Holds Promise in Multiple Myeloma

Jared Kaltwasser
Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment strategies.
Patient and doctor discussing symptoms. | Image credit: Intelligent Horizons - stock.adobe.com.jpeg
April 3rd 2025

PROs Associated With Survival, AEs in Multiple Myeloma

Jared Kaltwasser
The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning treatment in multiple myeloma.
Ajai Chari, MD
March 27th 2025

Optimizing Patient Selection for CAR T, Bispecifics Mitigates Adverse Events in High-Risk MM

Kyle Munz Ajai Chari, MD
For higher-risk multiple myeloma (MM), successful patient selection and monitoring strategies are vital for the management of adverse events and the disease itself.
Ajai Chari, MD
March 25th 2025

Making Bispecific Therapies Work in Community Settings

Kyle Munz Ajai Chari, MD
Ajai Chari, MD, stresses the importance of making bispecific therapies more accessible at the community level to improve outcomes in multiple myeloma.
12345678
...
12>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo